Drugs Made In America Acquisition Corp. (DMAA) stock
Close on Nov 11, 2026Market cap $264.62MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $264.62M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- $6.09M
Trading
- Previous close
- $10.90
- Open
- $10.90
- Day's range
- $10.89 – $10.91
- Volume
- 36,985
- Average volume (20 days)
- 12,821
- 52-week range
- $10.31 – $10.91
- RSI (14 days)
- 68.3
- Volatility (1 year)
- 1.9%
- Relative volume
- 1.49×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | DMAA | S&P 500 | Difference | DMAA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.5% | -2.4% | +2.9 pts | ||
| 3 months | +1.8% | -1.2% | +2.9 pts | ||
| Year to date | +5.1% | +12.3% | −7.2 pts | ||
| 1 year | +5.6% | +12.4% | −6.9 pts |
Two years at a glance
Fiscal years 2024 to 2025 and trailing twelve months, USD
Operating income
Net income
Press releases
Releases Drugs Made In America Acquisition filed with the SEC as exhibits to Form 8-K or 6-K
About Drugs Made In America Acquisition
Blank Checks
Drugs Made In America Acquisition Corp. is a blank check shell company formed to complete a merger, share exchange, asset acquisition, reorganization, or similar corporate transaction with one or more operating businesses. The company does not market commercial products, provide commercial services, or generate operational revenue. It currently maintains no distinct business operating segments and serves no direct commercial customers. Instead, the firm focuses its acquisition efforts on enterprises operating in artificial intelligence, pharmaceuticals, or other innovation-oriented industries that require developmental support.
Company profile, executives and historyDrugs Made In America Acquisition stock: common questions
What is Drugs Made In America Acquisition's stock price?
DMAA closed at $10.90 on Nov 11, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $10.31 and $10.91.
What is Drugs Made In America Acquisition's market cap?
Drugs Made In America Acquisition was worth $264.62M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
Does Drugs Made In America Acquisition pay a dividend?
No. Drugs Made In America Acquisition has not paid a cash dividend over the last twelve months.
How has DMAA stock performed over the past year?
Including dividends, DMAA returned +5.6% over the past year, against +12.4% for the S&P 500.
Who are Drugs Made In America Acquisition's competitors?
Companies most similar to Drugs Made In America Acquisition by business, industry and size include DMII, ADAC, OYSE, BLRK, NWAX.
See a number that looks wrong?